Abstract
Abnormal cellular proliferation is associated with the pathology of several diseases, including cancer, atherosclerosis and restenosis post-angioplasty. Therefore, anti-proliferative therapies may be a suitable approach to treat these disorders. Candidate targets for such strategies include specific components of the cell cycle machinery. Progression through the cell cycle in mammalian cells requires the activation of several cyclin-dependent protein kinases (CDKs) through their association with regulatory subunits called cyclins. Active CDK/cyclin holoenzymes phosphorylate cellular proteins including the retinoblastoma susceptibility gene product (pRb) and the related pocket proteins p107 and p130. Several compounds have been described that directly or indirectly inhibit the activity of CDKs, which results in a suppression of cell growth. In this review, we will discuss the use of drugs targeting CDKs and their therapeutic application in animal models and clinical trials.
Keywords: Inhibition, Cellular proliferation, Drug targeting, Cyclin dependent kinases, Chemical inhibitors, Purines
Current Pharmaceutical Biotechnology
Title: Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases
Volume: 1 Issue: 1
Author(s): Ignacio Perez-Roger, Carmen Ivorra, Antonio Diez, Maria Jose Cortes, Enric Poch, Silvia M. Sanz-Gonzalez and Vicente Andres
Affiliation:
Keywords: Inhibition, Cellular proliferation, Drug targeting, Cyclin dependent kinases, Chemical inhibitors, Purines
Abstract: Abnormal cellular proliferation is associated with the pathology of several diseases, including cancer, atherosclerosis and restenosis post-angioplasty. Therefore, anti-proliferative therapies may be a suitable approach to treat these disorders. Candidate targets for such strategies include specific components of the cell cycle machinery. Progression through the cell cycle in mammalian cells requires the activation of several cyclin-dependent protein kinases (CDKs) through their association with regulatory subunits called cyclins. Active CDK/cyclin holoenzymes phosphorylate cellular proteins including the retinoblastoma susceptibility gene product (pRb) and the related pocket proteins p107 and p130. Several compounds have been described that directly or indirectly inhibit the activity of CDKs, which results in a suppression of cell growth. In this review, we will discuss the use of drugs targeting CDKs and their therapeutic application in animal models and clinical trials.
Export Options
About this article
Cite this article as:
Perez-Roger Ignacio, Ivorra Carmen, Diez Antonio, Cortes Jose Maria, Poch Enric, Sanz-Gonzalez M. Silvia and Andres Vicente, Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases, Current Pharmaceutical Biotechnology 2000; 1 (1) . https://dx.doi.org/10.2174/1389201010001010107
DOI https://dx.doi.org/10.2174/1389201010001010107 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Gene Therapy for Bladder Cancer
Current Gene Therapy Opportunities to Improve the Prevention and Treatment of Cervical Cancer
Current Molecular Medicine Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry Biochemical Mechanisms of Cisplatin Cytotoxicity
Anti-Cancer Agents in Medicinal Chemistry Role of Advanced Glycation End Products (AGEs) and Oxidative Stress in Diabetic Retinopathy
Current Pharmaceutical Design Sirtuin Family: A Link to Metabolic Signaling and Senescence
Current Medicinal Chemistry The Development of MetAP-2 Inhibitors in Cancer Treatment
Current Medicinal Chemistry 7-aa Peptide Mimic from HVR1 of HCV Protects Hepatic Injury in Rats by Reduced Expression of Key Pro-Inflammatory Factors
Inflammation & Allergy - Drug Targets (Discontinued) Targeted Theranostics Against Solid Cancer Using Metal Bond Milk Protein and Aptamers
Current Topics in Medicinal Chemistry Target Driven Preclinical Screening for New Antimitotic Chemotherapy Agents
Current Topics in Medicinal Chemistry Discovery and Development of Purine-Scaffold Hsp90 Inhibitors
Current Topics in Medicinal Chemistry Overcoming Antibiotic Resistance: Insights from Clostridium difficile and the RB Tumor Suppressor
Protein & Peptide Letters Molecular Dynamics, Density Functional Theory, Pharmacophore Modeling, Molecular Interaction Fields and ADME/Tox Investigation of Novel Bioactive Compounds Interacting with CDK2 Surfaces
Current Physical Chemistry Subtype Selectivity in Phosphodiesterase 4 (PDE4): A Bottleneck in Rational Drug Design
Current Pharmaceutical Design The Role of Wnt/Beta-Catenin Signaling in Renal Carcinogenesis: Lessons from Cadmium Toxicity Studies
Current Molecular Medicine Seocalcitol (EB 1089) A Vitamin D Analogue of Anti-cancer Potential. Background, Design, Synthesis, Pre-clinical and Clinical Evaluation
Current Pharmaceutical Design BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
Current Cancer Drug Targets Anti-Apoptotic Genes in the Survival of Monocytic Cells During Infection
Current Genomics Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design Atoh1: Landscape for Inner Ear Cell Regeneration
Current Gene Therapy